(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

ARIMIDEX

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

ARIMIDEX

ST13

US500000073794256

Class

5

Filing

73794256

Registration

1753552

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

37

Latest update

01/11/2023

Trademark type

Word

Nice classes

5

Filing date

04/19/1989

Registration date

02/23/1993

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

01/11/2023

Last transaction

01/11/2023

Responsible office

United States Patent and Trademark Office

Status code

800

Official register

Principal Register

Filing basis

Foreign priority

Drawing code

1

Owner type

16

Owner location

Cambridge, GB

Examiner

TAYLOR, CRAIG

Law office

J80

Current location

GENERIC WEB UPDATE

Holders and representatives

Holders

ASTRAZENECA UK LIMITED
ZENECA LIMITED
IMPERIAL CHEMICAL INDUSTRIES PLC

Representatives

Cara M. Kearney AstraZeneca Pharmaceuticals LP

Technical classification

Nice Classes

Class 5

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

PHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND/OR TREATMENT OF CANCER

Publications

History of USPTO decisions and trademark events.

37 publications found

NA89

NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED

01/11/2023

RNL3

REGISTERED AND RENEWED (THIRD RENEWAL - 10 YRS)

01/11/2023

89AG

REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED

01/11/2023

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

01/11/2023

E89R

TEAS SECTION 8 & 9 RECEIVED

06/27/2022

REM2

COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED

02/23/2022

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

07/22/2021

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

07/22/2021

ECDR

TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS

07/22/2021

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

07/22/2021

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

07/22/2021

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

07/22/2021

NA89

NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED

06/04/2012

RNL2

REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)

06/04/2012

89AG

REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED

06/04/2012

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

06/04/2012

E89R

TEAS SECTION 8 & 9 RECEIVED

05/22/2012

CFIT

CASE FILE IN TICRS

10/12/2007

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

07/30/2007

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

07/30/2007

RNL1

REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)

06/16/2003

89AG

REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED

06/16/2003

89AF

REGISTERED - COMBINED SECTION 8 (10-YR) & SEC. 9 FILED

02/24/2003

MAIL

PAPER RECEIVED

02/24/2003

C15A

REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.

03/29/1999

815F

REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED

11/12/1998

R.PR

REGISTERED-PRINCIPAL REGISTER

02/23/1993

PUBO

PUBLISHED FOR OPPOSITION

12/01/1992

NPUB

NOTICE OF PUBLICATION

10/30/1992

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

08/25/1992

CNSI

INQUIRY AS TO SUSPENSION MAILED

04/17/1992

CNSL

LETTER OF SUSPENSION MAILED

11/05/1991

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

10/10/1991

CNSI

INQUIRY AS TO SUSPENSION MAILED

05/02/1991

DOCK

ASSIGNED TO EXAMINER

05/01/1991

CNSL

LETTER OF SUSPENSION MAILED

07/03/1989

DOCK

ASSIGNED TO EXAMINER

06/29/1989

Continuous trademark protection

Get notified about every new filing that threatens ARIMIDEX or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.